you will attend an initial visit after joining the study. during this visit you will give informed consent, provide your medical history, and undergo baseline examinations such as blood tests and physical measurements.

after the initial assessments you will be randomly assigned to one of two sequences. the sequences determine whether you receive the medication while fasted first and fed later, or fed first and fasted later.

you will receive a single oral dose of bms-986158 in a 3 mg soft gelatin capsule.

if your assigned condition is fasted, you will fast overnight (no food or drink except water) before taking the capsule with a glass of water and will remain without food for several hours after dosing.

if your assigned condition is fed, you will eat a high‑fat, high‑calorie meal as instructed, then take the capsule with a glass of water shortly after the meal.

blood samples will be taken at multiple time points after the dose to measure how the drug is absorbed in your body.

after the first dosing period you will have a washout interval during which no study medication is taken. this interval allows the drug to be cleared from your system before the next dosing period.

you will receive a second single oral dose of bms-986158 3 mg capsule under the opposite condition from the first period (fed if the first was fasted, or fasted if the first was fed).

the same procedures for taking the medication and for blood sampling will be followed as in the first dosing period.

throughout both dosing periods you will be asked to report any side effects or health changes.

regular safety checks, including vital signs and laboratory tests, will be performed to monitor your well‑being.

at the end of the study you will attend a final visit for concluding examinations, repeat laboratory tests, and a summary of the study procedures you completed.